Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Engineered LINC MIR503HG-loaded extracellular vesicles maintain stemness and pluripotency during long-term hiPSCs culture

Zhu J., Zhu X., Feng W., Jin Y., Ge X., Li Y.

Laboratory Study on Hip, published in Bioact Mater (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Bioact Mater (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41551196
PMCID
PMC12809747
DOI
10.1016/j.bioactmat.2025.12.023

Abstract (original English)

The reduction of stemness and pluripotency during the prolonged culture of hiPSCs poses a significant challenge in regenerative medicine. This study identified LINC MIR503HG as a factor involved in maintaining hiPSCs stemness. Consequently, it developed a highly efficient delivery system based on ADSC-EVs, named MIR503HG-EVs, to optimize the culture strategy for hiPSCs. During the extended culture, MIR503HG-EV-treated hiPSCs developed into colonies with more compact morphology, an increased percentage of viable cells, as well as elevated OCT4, SOX2, and NANOG expression. Furthermore, these cells maintained their chromosomal integrity, as no karyotypic anomalies were detected. Mechanistic studies demonstrated that MIR503HG selectively bound AHCTF1 to facilitate the active nucleocytoplasmic transport of MYC mRNA. This resulted in significantly augmented MYC protein production, which activated the stemness regulatory network. Concurrently, MIR503HG-EVs mitigated the decline in differentiation potential of hiPSCs after several passages by modulating the chromatin accessibility of stemness transcription factors and modifying energy metabolism, including glycolysis and oxidative phosphorylation pathways. Moreover, treatment with MIR503HG-EVs significantly enhanced the differentiation efficiency of high-passage hiPSCs into definitive endoderm, pancreatic, and hepatic lineages, thereby

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research